Effect of novel CAAX peptidomimetic farnesyltransferase inhibitor on angiogenesis in vitro and in vivo

被引:43
作者
Gu, WZ [1 ]
Tahir, SK [1 ]
Wang, YC [1 ]
Zhang, HC [1 ]
Cherian, SP [1 ]
O'Connor, S [1 ]
Leal, JA [1 ]
Rosenberg, SH [1 ]
Ng, SC [1 ]
机构
[1] Abbott Labs, Pharmaceut Prod Res Div, Canc Res, Dept 4N6 AP92, Abbott Pk, IL 60064 USA
关键词
angiogenesis; farnesyltransferase inhibitor (FTI); ras; vascular endothelial growth factor (VEGF);
D O I
10.1016/S0959-8049(99)00132-X
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Ras oncogenes can contribute to tumour development by stimulating vascular endothelial growth factor (VEGF)-dependent angiogenesis. The effect of Ras on angiogenesis may be affected by farnesyltransferase inhibitors (FTI) since farnesylation of Pas is required for its biological activity. In this paper we evaluated the effect of A-170634, a novel and potent: CAAX FTI on angiogenesis. Human umbilical vein endothelial cell (HUVEC) tube formation and VEGF; secretion were used to assess the effect of A-170634 on angiogenesis in vitro. In vivo, nude mice were injected with the K-ras mutant colon carcinoma cell line HCT116 and treated subcutaneously with A-170634 using osmotic minipump infusion for 10 days. The effect of A-170634 on corneal angiogenesis in vivo was assessed using pellets containing hydron, VEGF, A-170634 or vehicle. In vitro, A-170634 selectively inhibited farnesyltransferase activity over the closely related geranylgeranyltransferase I, inhibited Pas processing, blocked anchorage-dependent and -independent growth of HCT116 K-ras mutated cells, decreased HUVEC capillary structure formation, decreased VEGF secretion from tumour cells and HUVEC growth stimulating activity in a dose-dependent manner. In vivo, tumour growth was decreased by 30% and vascularisation in and around the tumours tvas reduced by 41% following drug-treatment with no apparent toxicity to the animals. VEGF-induced corneal neovascularisation was reduced by 80% following A-170634 treatment for 7 days. The data presented here demonstrated that A-170634 was a potent and selective peptidomimetic CAAX FTI with anti-angiogenic properties. These results implied that A-170634 may affect tumour growth in vivo by one or more antitumour pathways. (C) 1999 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:1394 / 1401
页数:8
相关论文
共 41 条
[1]   VASCULAR ENDOTHELIAL GROWTH-FACTOR ACTS AS A SURVIVAL FACTOR FOR NEWLY FORMED RETINAL-VESSELS AND HAS IMPLICATIONS FOR RETINOPATHY OF PREMATURITY [J].
ALON, T ;
HEMO, I ;
ITIN, A ;
PEER, J ;
STONE, J ;
KESHET, E .
NATURE MEDICINE, 1995, 1 (10) :1024-1028
[2]   RAS GENES [J].
BARBACID, M .
ANNUAL REVIEW OF BIOCHEMISTRY, 1987, 56 :779-827
[3]   A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis [J].
Barrington, RE ;
Subler, MA ;
Rands, E ;
Omer, CA ;
Miller, PJ ;
Hundley, JE ;
Koester, SK ;
Troyer, DA ;
Bearss, DJ ;
Conner, MW ;
Gibbs, JB ;
Hamilton, K ;
Koblan, KS ;
Mosser, SD ;
O'Neill, TJ ;
Schaber, MD ;
Senderak, ET ;
Windle, JJ ;
Oliff, A ;
Kohl, NE .
MOLECULAR AND CELLULAR BIOLOGY, 1998, 18 (01) :85-92
[4]  
BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601
[5]  
BROWN LF, 1993, CANCER RES, V53, P4727
[6]  
Claffey KP, 1996, CANCER RES, V56, P172
[7]   AMINO-ACID AND CDNA SEQUENCES OF A VASCULAR ENDOTHELIAL-CELL MITOGEN THAT IS HOMOLOGOUS TO PLATELET-DERIVED GROWTH-FACTOR [J].
CONN, G ;
BAYNE, ML ;
SODERMAN, DD ;
KWOK, PW ;
SULLIVAN, KA ;
PALISI, TM ;
HOPE, DA ;
THOMAS, KA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (07) :2628-2632
[8]  
COX AD, 1997, BIOCHIM BIOPHYS ACTA, V1333, P51
[9]   THALIDOMIDE IS AN INHIBITOR OF ANGIOGENESIS [J].
DAMATO, RJ ;
LOUGHNAN, MS ;
FLYNN, E ;
FOLKMAN, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (09) :4082-4085
[10]   Tumor angiogenesis: A physiological process or genetically determined? [J].
DAmore, PA ;
Shima, DT .
CANCER AND METASTASIS REVIEWS, 1996, 15 (02) :205-212